title: Efficacy and safety of sitagliptin for the treatment of diabetes mellitus complicated by chronic liver injury.
abstract: OBJECTIVE
  To investigate the efficacy and safety of a dipeptidyl peptidase-4 inhibitor, sitagliptin, for treating diabetes mellitus complicated by chronic liver injury.
  
  
  METHODS
  Sitagliptin was administered for 13.7 ± 10.1 months to 122 patients with DM complicated by chronic liver injury (including 19 patients with liver cirrhosis), and changes in hemoglobin A1c (HbA1c) and liver enzymes (transaminases, etc.) were evaluated.
  
  
  RESULTS
  HbA1c was reduced from 8.48 ± 1.43% to 7.87 ± 1.35% (P < 0.001). Among liver enzymes, alanine aminotransferase (ALT) levels improved from 75.1 ± 45.2 to 65.8 ± 35.8 IU/L (P = 0.012) and gamma-glut amyl-trans peptidase from 155.2 ± 161.1 to 133.2 ± 127.4 IU/L (P = 0.044). Among the causes of liver injury, non-alcoholic fatty liver disease and alcoholic liver disease both showed the reductions in HbA1c with no deterioration of liver enzymes. An analysis of 19 patients with liver cirrhosis also showed reductions in HbA1c with no deterioration of liver enzymes.
  
  
  CONCLUSIONS
  It is suggested that sitagliptin can be administered effectively and safely to patients with diabetes mellitus complicated by chronic liver injury, including liver cirrhosis.
authors.affiliation: Department of Endocrinology and Metabolism, Tokyo Teishin Hospital, 2-14-23, Fujimi, Chiyoda-ku, Tokyo, 102-0071 Japan.
authors.forename: Masahiro
authors.initials: M
authors.lastname: Asakawa
authors.affiliation: Department of Gastroenterology, Tokyo Teishin Hospital, 2-14-23, Fujimi, Chiyoda-ku, Tokyo, 102-0071 Japan.
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Mitsui
authors.affiliation: Department of Molecular Endocrinology and Metabolism, Tokyo Medical and Dental University Hospital, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510 Japan.
authors.forename: Momoko
authors.initials: M
authors.lastname: Akihisa
authors.affiliation: Department of Endocrinology and Metabolism, Tokyo Teishin Hospital, 2-14-23, Fujimi, Chiyoda-ku, Tokyo, 102-0071 Japan.
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Sekine
authors.affiliation: Department of Endocrinology and Metabolism, Tokyo Teishin Hospital, 2-14-23, Fujimi, Chiyoda-ku, Tokyo, 102-0071 Japan.
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Niitsu
authors.affiliation: Department of Endocrinology and Metabolism, Tokyo Teishin Hospital, 2-14-23, Fujimi, Chiyoda-ku, Tokyo, 102-0071 Japan.
authors.forename: Arisa
authors.initials: A
authors.lastname: Kobayashi
authors.affiliation: Department of Endocrinology and Metabolism, Tokyo Teishin Hospital, 2-14-23, Fujimi, Chiyoda-ku, Tokyo, 102-0071 Japan.
authors.forename: Atsuko
authors.initials: A
authors.lastname: Miyake
authors.affiliation: Department of Gastroenterology, Tokyo Teishin Hospital, 2-14-23, Fujimi, Chiyoda-ku, Tokyo, 102-0071 Japan.
authors.forename: Naoaki
authors.initials: N
authors.lastname: Hashimoto
authors.affiliation: Department of Endocrinology and Metabolism, Tokyo Teishin Hospital, 2-14-23, Fujimi, Chiyoda-ku, Tokyo, 102-0071 Japan.
authors.forename: Mitsunobu
authors.initials: M
authors.lastname: Kawamura
authors.affiliation: Department of Molecular Endocrinology and Metabolism, Tokyo Medical and Dental University Hospital, 1-5-45, Yushima, Bunkyo-ku, Tokyo, 113-8510 Japan.
authors.forename: Yoshihiro
authors.initials: Y
authors.lastname: Ogawa
keywords: Chronic liver injury; Diabetes mellitus; Dipeptidyl peptidase-4 inhibitor; Sitagliptin